University of Virginia

The availability of drugs to delay clinical type 1 diabetes onset makes risk screening critical, but the field is still working on how to implement it.

A retrospective analysis found levels of lipid-based biomarkers such as eicosanoids and sphingolipids were linked with risk of the condition.